Intervention: Device

Targets: Postpartum hemorrhage

Impact Objectives: Develop new gold-standard intervention for PPH

Status: FDA Clearance 2020

Intervention: Biologics manufacturing technology platform

Targets: Polio, Measles, Rubella, COVID-19

Impact Objectives: Dramatic reductions in the cost of essential biologics; distributed manufacturing

Intervention: Vaccines and therapeutics

Targets: Anti-venom for snakebites, vaccines for tuberculosis and pertussis

Impact Objectives: High quality anti-venoms, increased access to Tdap vaccines in pregnancy, more effective protection against tuberculosis

Status: Anti-venom approval in India pending, other products in clinical studies

Intervention: Vaccine platform

Targets: Chikungunya, Zika, COVID-19

Impact Objectives: Protect at-risk communities from public health challenges such as mosquito-transmitted viruses

Status: Acquired by Merck in 2020. COVID-19 and chikungunya vaccines in development

Intervention: Surgical device

Targets: Cataract-induced blindness and visual impairment

Impact Objectives: Expand access to vision-restoring cataract surgery in resource-limited settings

Status: Acquired by Zeiss. Product FDA cleared.

Intervention: Treatment

Targets: Hookworm, Roundworm, Whipworm

Impact Objectives: Cure hundreds of millions of school-aged children from parasitic worm infections; expand arsenal of anthelmintics

Status: Discontinued

Intervention: Diagnostic

Targets: Malaria, G6PDd, HIV, dengue, HPV, Zika, COVID-19

Impact Objectives: Reduced cost of high-quality malaria RDTs; new, low-cost diagnostics for other diseases

Status: >100 million malaria tests per year; COVID-19 antibody and antigen tests approved

Intervention: Diagnostic

Targets: HIV, Ebola, HCV, malaria, COVID-19

Impact Objectives: Improved professional testing and self-testing

Status: IPO April 2020 tests for HIV, COVID-19 and pregnancy on the market

Intervention: Diagnostic

Targets: Preeclampsia (PE), gestational diabetes mellitus (GDM)

Impact Objectives: Early, affordable, point-of-care PE/GDM testing; ↓ maternal/infant mortality/morbidity

Status: Discontinued

Intervention: Diagnostic

Targets: Tuberculosis (TB), HCV, COVID-19

Impact Objectives: Diagnosis of TB and HCV on a near-point-of-care molecular diagnostic platform, enabling more effective treatment

Status: Approved for HCV and COVID-19 tests

Intervention: Vaccine

Targets: Cholera

Impact Objectives: Increase global supply of affordable vaccine doses; deliver improved presentation at $1/dose

Status: IPO 2017 over 50 million doses to date

Intervention: Treatment

Targets: Onchocerciasis (river blindness)

Impact Objectives: Accelerate the eradication of onchocerciasis; improve treatment outcomes

Status: FDA approved 2018; Priority Review Voucher sold in 2019 to Novo Nordisk

GHIF Portfolio Recap

A timeline depicting the history of GHIF investments
GHIF's continued impact list, the final slide.